Clinical Trial

A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study was to compare the antitumor activity of 9MW2821 and chemotherapy in participants with locally advanced or metastatic urothelial cancer previously treated with PD-(L)1 inhibitor and platinum-containing chemotherapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-12-25; most recent amendment 2025-04-10.
Status change: Not Yet Recruiting → Recruiting 2024-09-09
Trial Details
NCT Number NCT06196736
Lead Sponsor Mabwell (Shanghai) Bioscience Co., Ltd.
Conditions Advanced Urothelial Carcinoma
Enrollment 432 participants
Start Date 2023-12-29
Primary Completion 2026-09 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2025-04-13